El modelo de 6-hidroxidopamina y la fisiopatología parkinsoniana: nuevos hallazgos en un viejo modelo

Neurología - Tập 32 - Trang 533-539 - 2017
D. Hernandez-Baltazar1,2, L.M. Zavala-Flores3, A. Villanueva-Olivo4
1Cátedra CONACyT, Dirección Adjunta de Desarrollo Científico CONACyT, México, D. F., México
2Instituto de Neuroetología, Universidad Veracruzana, Xalapa, Veracruz, México
3Centro de Investigación Biomédica del Noreste, IMSS, Monterrey, Nuevo León, México
4Departamento de Histología, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, México

Tài liệu tham khảo

Dexter, 2013, Parkinson disease: From pathology to molecular disease mechanisms, Free Radic Res Med, 62, 132, 10.1016/j.freeradbiomed.2013.01.018

Sulzer, 2013, Neuronal vulnerability, pathogenesis, and Parkinson's disease, Mov Disord, 28, 41, 10.1002/mds.25095

Double, 2012, Neuronal vulnerability in Parkinson's disease, Parkinsonism Relat Disord, 18, S52, 10.1016/S1353-8020(11)70018-9

Chiueh, 1993, Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism, Adv Neurol, 60, 251

Langston, 1983, Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, N Engl J Med, 309, 310, 10.1056/NEJM198308043090511

Ungerstedt, 1968, 6-Hydroxy-dopamine induced degeneration of central monoamine neurons, Eur J Pharmacol, 5, 107, 10.1016/0014-2999(68)90164-7

Blesa, 2012, Classic and new animal models of Parkinson's disease, J Biomed Biotechnol, 2012, 845618, 10.1155/2012/845618

Blum, 2001, Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: Contribution to the apoptotic theory in Parkinson's disease, Prog Neurobiol, 65, 135, 10.1016/S0301-0082(01)00003-X

Altar, 1986, 1-Methyl-4-phenylpyridine (MPP+): Regional dopamine neuron uptake, toxicity, and novel rotational behavior following dopamine receptor proliferation, Eur J Pharmacol, 131, 199, 10.1016/0014-2999(86)90573-X

Ter Horst, 1992, Neurochemical lesioning in the rat brain with iontophoretic injection of the 1-methyl-4-phenylpyridinium ion (MPP+), Neurosci Lett, 141, 203, 10.1016/0304-3940(92)90895-E

Blesa, 2014, Parkinson's disease: Animal models and dopaminergic cell vulnerability, Front Neuroanat, 8, 155, 10.3389/fnana.2014.00155

Blandini, 2012, Animal models of Parkinson's disease, FEBS J, 279, 1156, 10.1111/j.1742-4658.2012.08491.x

Chiba, 1984, Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase, Biochem Biophys Res Commun, 120, 574, 10.1016/0006-291X(84)91293-2

Jenner, 1992, New insights into the cause of Parkinson's disease, Neurology, 42, 2241, 10.1212/WNL.42.12.2241

Harrison, 2005, Oxidative stress-induced apoptosis in neurons correlates with mitochondrial DNA base excision repair pathway imbalance, Nucleic Acids Res, 33, 4660, 10.1093/nar/gki759

Singh, 2010, Involvement of the mitochondrial apoptotic pathway and nitric oxide synthase in dopaminergic neuronal death induced by 6-hydroxydopamine and lipopolysaccharide, Redox Rep, 15, 115, 10.1179/174329210X12650506623447

Perese, 1989, A 6-hydroxydopamine-induced selective parkinsonian rat model, Brain Res, 494, 285, 10.1016/0006-8993(89)90597-0

Venero, 1997, Time course changes in the dopaminergic nigrostriatal system following transection of the medial forebrain bundle: Detection of oxidatively modified proteins in substantia nigra, J Neurochem, 68, 2458, 10.1046/j.1471-4159.1997.68062458.x

Stanic, 2003, Timecourse of striatal re-innervation following lesions of dopaminergic SNpc neurons of the rat, Eur J Neurosci, 18, 1175, 10.1046/j.1460-9568.2003.02800.x

Stanic, 2003, Changes in function and ultrastructure of striatal dopaminergic terminals that regenerate following partial lesions of the SNpc, J Neurochem, 86, 329, 10.1046/j.1471-4159.2003.01843.x

Decressac, 2012, Comparison of the behavioural and histological characteristics of the 6-OHDA and alpha-synuclein rat models of Parkinson's disease, Exp Neurol, 235, 306, 10.1016/j.expneurol.2012.02.012

Hernandez-Baltazar, 2013, Activation of GSK-3beta and caspase-3 occurs in nigral dopamine neurons during the development of apoptosis activated by a striatal injection of 6-hydroxydopamine, PloS One, 8, e70951, 10.1371/journal.pone.0070951

Kirik, 1998, Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat, Exp Neurol, 152, 259, 10.1006/exnr.1998.6848

Mercanti, 2012, A 6-hydroxydopamine in vivo model of Parkinson's disease, Methods Mol Biol, 846, 355, 10.1007/978-1-61779-536-7_30

Da Rocha, 2013, Diphenyl diselenide reduces mechanical and thermal nociceptive behavioral responses after unilateral intrastriatal administration of 6-hydroxydopamine in rats, Biol Trace Elem Res, 154, 372, 10.1007/s12011-013-9736-2

Healy-Stoffel, 2012, A novel use of combined tyrosine hydroxylase and silver nucleolar staining to determine the effects of a unilateral intrastriatal 6-hydroxydopamine lesion in the substantia nigra: A stereological study, J Neurosci Methods, 210, 187, 10.1016/j.jneumeth.2012.07.013

Kelsey, 2009, The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat, Psychopharmacology, 201, 529, 10.1007/s00213-008-1319-0

Heuer, 2012, Unilateral nigrostriatal 6-hydroxydopamine lesions in mice I: Motor impairments identify extent of dopamine depletion at three different lesion sites, Behav Brain Res, 228, 30, 10.1016/j.bbr.2011.11.027

Roedter, 2001, Comparison of unilateral and bilateral intrastriatal 6-hydroxydopamine-induced axon terminal lesions: evidence for interhemispheric functional coupling of the two nigrostriatal pathways, J Comp Neurol, 432, 217, 10.1002/cne.1098

Amalric, 1995, Complex deficits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat, Eur J Neurosci, 7, 972, 10.1111/j.1460-9568.1995.tb01085.x

Deumens, 2002, Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway, Exp Neurol, 175, 303, 10.1006/exnr.2002.7891

Brichta, 2014, Molecular determinants of selective dopaminergic vulnerability in Parkinson's disease: An update, Front Neuroanat, 8, 152, 10.3389/fnana.2014.00152

Walsh, 2014, The heterogeneity of ventral tegmental area neurons: Projection functions in a mood-related context, Neuroscience, 282C, 101, 10.1016/j.neuroscience.2014.06.006

Lindgren, 2012, Do alpha-synuclein vector injections provide a better model of Parkinson's disease than the classic 6-hydroxydopamine model, Exp Neurol, 237, 36, 10.1016/j.expneurol.2012.05.022

Tai, 2014, Protective effect of alpha-synuclein knockdown on methamphetamine-induced neurotoxicity in dopaminergic neurons, Neural Regen Res, 9, 951, 10.4103/1673-5374.133146

He, 2015, Treatment with trehalose prevents behavioral and neurochemical deficits produced in an AAV alpha-synuclein rat model of Parkinson's disease, Mol Neurobiol

Roostaee, 2013, Aggregation and neurotoxicity of recombinant alpha-synuclein aggregates initiated by dimerization, Mol Neurodegener, 8, 5, 10.1186/1750-1326-8-5

Razgado-Hernandez, 2015, The transfection of BDNF to dopamine neurons potentiates the effect of dopamine d3 receptor agonist recovering the striatal innervation, dendritic spines and motor behavior in an aged rat model of Parkinson's disease, PloS One, 10, e0117391, 10.1371/journal.pone.0117391

Chen, 2014, Intrastriatal GDNF gene transfer by inducible lentivirus vectors protects dopaminergic neurons in a rat model of parkinsonism, Exp Neurol, 261, 87, 10.1016/j.expneurol.2014.06.022

Herran, 2014, Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease, Int J Nanomedicine, 9, 2677

Deng, 2013, Co-transplantation of GDNF-overexpressing neural stem cells and fetal dopaminergic neurons mitigates motor symptoms in a rat model of Parkinson's disease, PloS One, 8, e80880, 10.1371/journal.pone.0080880

Gonzalez-Barrios, 2006, Neurotensin polyplex as an efficient carrier for delivering the human GDNF gene into nigral dopamine neurons of hemiparkinsonian rats, Mol Ther, 14, 857, 10.1016/j.ymthe.2006.09.001

Nadella, 2014, Transient transfection of human CDNF gene reduces the 6-hydroxydopamine-induced neuroinflammation in the rat substantia nigra, J. Neuroinflammation, 11, 209, 10.1186/s12974-014-0209-0

Cordero-Llana, 2015, Enhanced efficacy of the CDNF/MANF family by combined intranigral overexpression in the 6-OHDA rat model of Parkinson's disease, Mol Ther, 23, 244, 10.1038/mt.2014.206

Kulkarni, 2015, Nanotechnology-mediated nose to brain drug delivery for Parkinson's disease: A mini review, J Drug Target, 1

Iqbal, 2013, Nanoneurotoxicity to nanoneuroprotection using biological and computational approaches, J Environ Sci Health C Environ Carcinog Ecotoxicol Rev, 31, 256, 10.1080/10590501.2013.829706

Pardo, 2014, Gene therapy and cell reprogramming for the aging brain: achievements and promise, Current gene therapy, 14, 24, 10.2174/1566523214666140120121733

Allen, 2014, Gene-based therapies in Parkinson's disease, Neurotherapeutics, 11, 60, 10.1007/s13311-013-0233-2

Hirsch, 1997, Neuronal vulnerability in Parkinson's disease, J. Neural Transm, 50, 79, 10.1007/978-3-7091-6842-4_9

Double, 2003, Iron-binding characteristics of neuromelanin of the human substantia nigra, Biochem Pharmacol, 66, 489, 10.1016/S0006-2952(03)00293-4

Gerlach, 2008, Neuromelanin-bound ferric iron as an experimental model of dopaminergic neurodegeneration in Parkinson's disease, Parkinsonism Relat Disord, 14, S185, 10.1016/j.parkreldis.2008.04.028

Nemoto, 1999, Calretinin and calbindin-D28k in dopaminergic neurons of the rat midbrain: A triple-labeling immunohistochemical study, Brain Res, 846, 129, 10.1016/S0006-8993(99)01950-2

Tsuboi, 2000, Calretinin-containing axons and neurons are resistant to an intrastriatal 6-hydroxydopamine lesion, Brain Res, 866, 55, 10.1016/S0006-8993(00)02219-8

Ferger, 2001, 6-hydroxydopamine increases hydroxyl free radical production and DNA damage in rat striatum, Neuroreport, 12, 1155, 10.1097/00001756-200105080-00021

Sanchez-Iglesias, 2007, Time-course of brain oxidative damage caused by intrastriatal administration of 6-hydroxydopamine in a rat model of Parkinson's disease, Neurochem Res, 32, 99, 10.1007/s11064-006-9232-6

Middeldorp, 2011, GFAP in health and disease, Prog Neurobiol, 93, 421, 10.1016/j.pneurobio.2011.01.005

Walsh, 2011, Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat, Neuroscience, 175, 251, 10.1016/j.neuroscience.2010.12.005

Aguzzi, 2013, Microglia: scapegoat, saboteur, or something else, Science, 339, 156, 10.1126/science.1227901

Rodrigues, 2004, Astroglial and microglial activation in the wistar rat ventral tegmental area after a single striatal injection of 6-hydroxydopamine, Int J Neurosci, 114, 197, 10.1080/00207450490249338

Stott, 2014, Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson's disease, Eur J Neurosci, 39, 1042, 10.1111/ejn.12459

Sauer, 1994, Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat, Neuroscience, 59, 401, 10.1016/0306-4522(94)90605-X

Tobon-Velasco, 2013, 6-OHDA-induced apoptosis and mitochondrial dysfunction are mediated by early modulation of intracellular signals and interaction of Nrf2 and NF-kappaB factors, Toxicology, 304, 109, 10.1016/j.tox.2012.12.011

Bernstein, 2011, 6-OHDA generated ROS induces DNA damage and p53- and PUMA-dependent cell death, Mol Neurodegener, 6, 2, 10.1186/1750-1326-6-2

Marti, 2002, Striatal 6-hydroxydopamine induces apoptosis of nigral neurons in the adult rat, Brain Res, 958, 185, 10.1016/S0006-8993(02)03694-6

Ichitani, 1994, Biochemical and immunocytochemical changes induced by intrastriatal 6-hydroxydopamine injection in the rat nigrostriatal dopamine neuron system: Evidence for cell death in the substantia nigra, Exp Neurol, 130, 269, 10.1006/exnr.1994.1205

Kostrzewa, 2000, Review of apoptosis vs necrosis of substantia nigra pars compacta in Parkinson's disease, Neurotox Res, 2, 239, 10.1007/BF03033797

Blandini, 2007, Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: New clues from an old model, Eur J Neurosci, 25, 397, 10.1111/j.1460-9568.2006.05285.x

Zuch, 2000, Time course of degenerative alterations in nigral dopaminergic neurons following a 6-hydroxydopamine lesion, J Comp Neurol, 427, 440, 10.1002/1096-9861(20001120)427:3<440::AID-CNE10>3.0.CO;2-7

Charriaut-Marlangue, 1995, A cautionary note on the use of the TUNEL stain to determine apoptosis, Neuroreport, 7, 61, 10.1097/00001756-199512000-00014

Ito, 2006, Method of specific detection of apoptosis using formamide-induced DNA denaturation assay, J Histochem Cytochem, 54, 683, 10.1369/jhc.5A6799.2006

In, 2015, Inhibition of mitochondrial clearance and Cu/Zn-SOD activity enhance 6-hydroxydopamine-induced neuronal apoptosis, Mol Neurobiol

Marin, 2011, In vivo 6-OHDA-induced neurodegeneration and nigral autophagic markers expression, Neurochem Int, 58, 521, 10.1016/j.neuint.2011.01.010

Giordano, 2014, Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease, Redox Biology, 2, 82, 10.1016/j.redox.2013.12.013

Jellinger, 2001, Cell death mechanisms in neurodegeneration, J Cell Mol Med, 5, 1, 10.1111/j.1582-4934.2001.tb00134.x

D’Amelio, 2012, Caspase-3 in the central nervous system: Beyond apoptosis, Trends Neurosci, 35, 700, 10.1016/j.tins.2012.06.004

Han, 2003, Caspase-dependent and -independent cell death pathways in primary cultures of mesencephalic dopaminergic neurons after neurotoxin treatment, J Neurosci, 23, 5069, 10.1523/JNEUROSCI.23-12-05069.2003

Cutillas, 1999, Caspase inhibition protects nigral neurons against 6-OHDA-induced retrograde degeneration, Neuroreport, 10, 2605, 10.1097/00001756-199908200-00030

Oo, 2002, Distinct nuclear and cytoplasmic localization of caspase cleavage products in two models of induced apoptotic death in dopamine neurons of the substantia nigra, Exp Neurol, 175, 1, 10.1006/exnr.2002.7881

Hanrott, 2006, 6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta, J Biol Chem, 281, 5373, 10.1074/jbc.M511560200

Jeon, 1999, Activation of caspase-3 in developmental models of programmed cell death in neurons of the substantia nigra, J Neurochem, 73, 322, 10.1046/j.1471-4159.1999.0730322.x

Ebert, 2008, Progressive degeneration of dopamine neurons in 6-hydroxydopamine rat model of Parkinson's disease does not involve activation of caspase-9 and caspase-3, Neurosci Res, 86, 317, 10.1002/jnr.21480

Kim, 2011, Dissociation of progressive dopaminergic neuronal death and behavioral impairments by Bax deletion in a mouse model of Parkinson's diseases, PloS One, 6, e25346, 10.1371/journal.pone.0025346

Burguillos, 2011, Caspase signalling controls microglia activation and neurotoxicity, Nature, 472, 319, 10.1038/nature09788

Venero, 2013, Caspases playing in the field of neuroinflammation: Old and new players, Dev Neurosci, 35, 88, 10.1159/000346155

Gomez-Sintes, 2011, GSK-3 mouse models to study neuronal apoptosis and neurodegeneration, Front Mol Neurosci, 4, 45, 10.3389/fnmol.2011.00045

Golpich, 2015, Glycogen synthase kinase-3 beta (GSK-3beta) signaling: Implications for Parkinson's disease, Pharmacol Res, 97, 16, 10.1016/j.phrs.2015.03.010

Thông tin
Thông tin xuất bản

Neurología

Tập 32

533-539

Thông tin tác giả